Celgene Corp (CELG) 87.46 $CELG
Final Glance: Biotechnology companies
AP - Mon Aug 04, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Mon Aug 04, 12:26PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Amgen Cancer Drug Kyprolis Succeeds In Trial
at Investor's Business Daily - Mon Aug 04, 9:56AM CDT
Big biotech Amgen (AMGN) early Monday reported positive interim results from a crucial late-stage trial of blood-cancer drug Kyprolis Monday, helping justify its $10 billion acquisition of Onyx last year. Amgen was up more than 1% in early trading in...
Early Glance: Biotechnology companies
AP - Mon Aug 04, 9:32AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Celgene (CELG) Approaches New Upside Target of $88.55
Comtex SmarTrend(R) - Mon Aug 04, 9:08AM CDT
Shares of Celgene (NASDAQ:CELG) opened today above their pivot of $86.90 and have already reached the first level of resistance at $87.60. Analysts will be watching for a cross of the next upside pivot targets of $88.55 and $90.20.
Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Aug 04, 8:20AM CDT
Acorda (ACOR) recorded an improvement in Ampyra revenues and continues to expect Ampyra sales in the range of $328 million - $335 million.
Use of Priority Review Voucher and Financial Result Releases of Healthcare Companies - Research Reports on Regeneron, WellPoint, Edwards, Humana and Celgene
PR Newswire - Mon Aug 04, 8:20AM CDT
Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), WellPoint Inc. (NYSE: WLP), Edwards Lifesciences Corp. (NYSE: EW), Humana Inc. (NYSE: HUM) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5412-100free.
Pharmacyclics Incurs Q2 Loss, Revenues Up on Imbruvica Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 4:10PM CDT
Pharmacyclics (PCYC) reported better than expected revenues on strong Imbruvica sales.
Endo International Beats on Q2 Earnings & Sales, Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:36PM CDT
Endo (ENDP) reported higher-than-expected earnings and revenues in the quarter.
Pharmacyclics Q2 Earnings Get Mixed Reception
at Investor's Business Daily - Fri Aug 01, 11:35AM CDT
Biotech Pharmacyclics (PCYC) was seesawing on the stock market today after its Q2 sales beat consensus late Thursday, but the company declined to update its guidance. Pharmacyclics' sales more than doubled over the year-earlier quarter to $113...
Incyte Posts Wider-than-Expected Q2 Loss, Raises Sales View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 10:17AM CDT
Incyte Corporation (INCY) reported a loss of 22 cents per share in the second quarter of 2014, significantly wider than the Zacks Consensus Estimate of a loss of 9 cents.
Celgene Up 18.4% Since SmarTrend Uptrend Call (CELG)
Comtex SmarTrend(R) - Fri Aug 01, 9:15AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 3 months, Celgene has returned 18.39% as of today's recent price of $87.53.
BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 4:00PM CDT
BioMarin (BMRN) reported a narrower-than-expected loss aided by higher revenues.
United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 12:20PM CDT
Lower costs and higher revenues helped United Therapeutics (UTHR) deliver better-than-expected earnings.
Final Glance: Biotechnology companies
AP - Mon Aug 04, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Mon Aug 04, 12:26PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Amgen Cancer Drug Kyprolis Succeeds In Trial
at Investor's Business Daily - Mon Aug 04, 9:56AM CDT
Big biotech Amgen (AMGN) early Monday reported positive interim results from a crucial late-stage trial of blood-cancer drug Kyprolis Monday, helping justify its $10 billion acquisition of Onyx last year. Amgen was up more than 1% in early trading in...
Early Glance: Biotechnology companies
AP - Mon Aug 04, 9:32AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Celgene (CELG) Approaches New Upside Target of $88.55
Comtex SmarTrend(R) - Mon Aug 04, 9:08AM CDT
Shares of Celgene (NASDAQ:CELG) opened today above their pivot of $86.90 and have already reached the first level of resistance at $87.60. Analysts will be watching for a cross of the next upside pivot targets of $88.55 and $90.20.
Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Aug 04, 8:20AM CDT
Acorda (ACOR) recorded an improvement in Ampyra revenues and continues to expect Ampyra sales in the range of $328 million - $335 million.
Use of Priority Review Voucher and Financial Result Releases of Healthcare Companies - Research Reports on Regeneron, WellPoint, Edwards, Humana and Celgene
PR Newswire - Mon Aug 04, 8:20AM CDT
Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), WellPoint Inc. (NYSE: WLP), Edwards Lifesciences Corp. (NYSE: EW), Humana Inc. (NYSE: HUM) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5412-100free.
Pharmacyclics Incurs Q2 Loss, Revenues Up on Imbruvica Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 4:10PM CDT
Pharmacyclics (PCYC) reported better than expected revenues on strong Imbruvica sales.
Endo International Beats on Q2 Earnings & Sales, Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:36PM CDT
Endo (ENDP) reported higher-than-expected earnings and revenues in the quarter.
Pharmacyclics Q2 Earnings Get Mixed Reception
at Investor's Business Daily - Fri Aug 01, 11:35AM CDT
Biotech Pharmacyclics (PCYC) was seesawing on the stock market today after its Q2 sales beat consensus late Thursday, but the company declined to update its guidance. Pharmacyclics' sales more than doubled over the year-earlier quarter to $113...
Incyte Posts Wider-than-Expected Q2 Loss, Raises Sales View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 10:17AM CDT
Incyte Corporation (INCY) reported a loss of 22 cents per share in the second quarter of 2014, significantly wider than the Zacks Consensus Estimate of a loss of 9 cents.
Celgene Up 18.4% Since SmarTrend Uptrend Call (CELG)
Comtex SmarTrend(R) - Fri Aug 01, 9:15AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 3 months, Celgene has returned 18.39% as of today's recent price of $87.53.
BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 4:00PM CDT
BioMarin (BMRN) reported a narrower-than-expected loss aided by higher revenues.
United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 12:20PM CDT
Lower costs and higher revenues helped United Therapeutics (UTHR) deliver better-than-expected earnings.
